Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
DexCom
DXCM
5
Collegium Pharmaceutical
COLL
(Q3)Jan 31, 2025 | (Q2)Oct 31, 2024 | (Q1)Jul 31, 2024 | (FY)Apr 30, 2024 | (Q4)Apr 30, 2024 | (Q3)Jan 31, 2024 | (Q2)Oct 31, 2023 | (Q1)Jul 31, 2023 | (FY)Apr 30, 2023 | (Q4)Apr 30, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Current assets | ||||||||||
Cash, cash equivalents and short term investments | 1,087.18%3.36M | 1,945.73%4.09M | -29.58%1.19M | -92.69%376.05K | -92.69%376.05K | -96.16%282.87K | -97.82%200.08K | -85.29%1.7M | -63.45%5.14M | -63.45%5.14M |
-Cash and cash equivalents | 1,087.18%3.36M | 1,945.73%4.09M | -29.58%1.19M | -92.69%376.05K | -92.69%376.05K | -96.16%282.87K | -97.82%200.08K | -85.29%1.7M | -63.45%5.14M | -63.45%5.14M |
Prepaid assets | 89.62%589.21K | 15.79%673.67K | -69.06%222.24K | -88.60%79.19K | -88.60%79.19K | -70.15%310.74K | -49.48%581.8K | 24.23%718.19K | 98.71%694.92K | 98.71%694.92K |
Total current assets | 564.98%3.95M | 509.65%4.77M | -41.32%1.42M | -92.20%455.24K | -92.20%455.24K | -92.95%593.61K | -92.43%781.88K | -80.08%2.41M | -59.51%5.84M | -59.51%5.84M |
Non current assets | ||||||||||
Net PPE | 20.77%228.29K | 19.46%240.98K | 18.31%253.66K | 120.87%176.35K | 120.87%176.35K | 121.96%189.03K | 122.92%201.72K | 123.77%214.4K | -22.41%79.84K | -22.41%79.84K |
Total non current assets | 20.77%228.29K | 19.46%240.98K | 18.31%253.66K | 120.87%176.35K | 120.87%176.35K | 121.96%189.03K | 122.92%201.72K | 123.77%214.4K | -22.41%79.84K | -22.41%79.84K |
Total assets | 433.53%4.18M | 409.12%5.01M | -36.46%1.67M | -89.32%631.59K | -89.32%631.59K | -90.79%782.64K | -90.56%983.6K | -78.48%2.63M | -59.25%5.92M | -59.25%5.92M |
Liabilities | ||||||||||
Current liabilities | ||||||||||
Payables | ---- | ---- | ---- | 1.91%2.93M | 1.91%2.93M | ---- | ---- | 166.44%2.74M | 146.38%2.87M | 146.38%2.87M |
-accounts payable | ---- | ---- | ---- | 1.91%2.93M | 1.91%2.93M | ---- | ---- | 166.44%2.74M | 146.82%2.87M | 146.82%2.87M |
Current debt and capital lease obligation | ---- | ---- | ---- | --300.71K | --300.71K | ---- | ---- | ---- | ---- | ---- |
-Current debt | ---- | ---- | ---- | --300.71K | --300.71K | ---- | ---- | ---- | ---- | ---- |
Current liabilities | -81.03%725.85K | -65.77%1.25M | 5.15%2.88M | 12.39%3.23M | 12.39%3.23M | 44.81%3.83M | 123.89%3.67M | 166.44%2.74M | 146.38%2.87M | 146.38%2.87M |
Non current liabilities | ||||||||||
Derivative product liabilities | ---- | ---- | ---- | ---- | ---- | --742.26K | ---- | ---- | ---- | ---- |
Preferred securities outside stock equity | ---- | ---- | ---- | ---- | ---- | --477.74K | ---- | ---- | ---- | ---- |
Total non current liabilities | --0 | --0 | --0 | --0 | --0 | --1.22M | --0 | --0 | --0 | --0 |
Total liabilities | -85.62%725.85K | -65.77%1.25M | 5.15%2.88M | 12.39%3.23M | 12.39%3.23M | 90.97%5.05M | 123.89%3.67M | 166.44%2.74M | 146.38%2.87M | 146.38%2.87M |
Shareholders'equity | ||||||||||
Share capital | -12.39%580 | -19.17%523 | -99.11%86 | 6.15%69 | 6.15%69 | -93.13%662 | -93.22%647 | 1.53%9.69K | -99.32%65 | -99.32%65 |
-common stock | -12.39%580 | -19.17%523 | -99.11%86 | 6.15%69 | 6.15%69 | -93.13%662 | -93.22%647 | 1.53%9.69K | -99.32%65 | -99.32%65 |
-Preferred stock | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
Retained earnings | -7.95%-57.4M | -11.69%-56.41M | -15.53%-54.99M | -22.57%-54.02M | -22.57%-54.02M | -30.42%-53.17M | -42.91%-50.51M | -47.68%-47.6M | -50.96%-44.07M | -50.96%-44.07M |
Paid-in capital | 24.24%60.85M | -4.05%60.16M | -13.76%53.78M | -17.06%51.43M | -17.06%51.43M | -20.37%48.97M | 6.27%62.7M | 6.99%62.36M | 7.98%62M | 7.98%62M |
Other equity interest | ---- | ---- | ---- | ---- | ---- | 99.53%-70K | 0.05%-14.88M | 0.00%-14.88M | 0.00%-14.88M | 0.00%-14.88M |
Total stockholders'equity | 180.91%3.45M | 239.91%3.75M | -973.96%-1.21M | -185.18%-2.59M | -185.18%-2.59M | -172.77%-4.26M | -130.53%-2.68M | -101.01%-112.88K | -77.19%3.05M | -77.19%3.05M |
Total equity | 180.91%3.45M | 239.91%3.75M | -973.96%-1.21M | -185.18%-2.59M | -185.18%-2.59M | -172.77%-4.26M | -130.53%-2.68M | -101.01%-112.88K | -77.19%3.05M | -77.19%3.05M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |